AI Engines For more Details: Perplexity Kagi Labs You
Mucolytic Action: Ambroxol hydrochloride works by thinning and loosening mucus in the respiratory tract, making it easier to cough up and clear from the airways. It promotes expectoration and helps relieve symptoms associated with respiratory conditions characterized by thick or excessive mucus production, such as acute and chronic bronchitis, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.
Cough Relief: In addition to its mucolytic action, ambroxol hydrochloride has mild cough-suppressant properties. It helps reduce the frequency and intensity of coughing by soothing irritated airway linings and decreasing the reflex stimulation of cough receptors.
Respiratory Conditions: Ambroxol hydrochloride is commonly used in the treatment of various respiratory conditions, including acute and chronic bronchitis, bronchiectasis, pneumonia, asthma, and COPD. It can help alleviate symptoms such as cough, chest congestion, and difficulty breathing associated with these conditions.
Secretion Clearance: Ambroxol hydrochloride may also enhance the clearance of respiratory secretions by stimulating the activity of ciliated cells in the airway epithelium. This can help improve mucociliary clearance and reduce the risk of respiratory tract infections.
Anti-inflammatory Effects: In addition to its mucolytic and expectorant actions, ambroxol hydrochloride has been reported to have anti-inflammatory effects in preclinical studies. It may help reduce inflammation in the respiratory tract and modulate immune responses, contributing to the overall management of respiratory conditions.
Safety Profile: Ambroxol hydrochloride is generally well tolerated when used as directed. Common side effects may include gastrointestinal symptoms such as nausea, vomiting, or diarrhea. These side effects are usually mild and transient and may resolve with continued use or dose adjustments. Allergic reactions to ambroxol hydrochloride are rare but can occur.
Contraindications: Ambroxol hydrochloride should be used with caution in patients with a history of gastric ulcers or gastrointestinal bleeding, as it may exacerbate these conditions. It is contraindicated in individuals with hypersensitivity to ambroxol or any of its components.
Drug Interactions: There are no significant drug interactions reported with ambroxol hydrochloride. However, caution should be exercised when using other medications that have sedative or depressant effects on the central nervous system concurrently, as they may potentiate the sedative effects of ambroxol hydrochloride.
Pregnancy and Lactation: The safety of ambroxol hydrochloride use during pregnancy and breastfeeding has not been well established. It is generally recommended to avoid using ambroxol hydrochloride during pregnancy unless the potential benefits outweigh the risks, and under the guidance of a healthcare professional.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.2 | -0.2 | |
ADHD | 1.5 | 1.5 | |
Age-Related Macular Degeneration and Glaucoma | 0 | 0 | |
Allergic Rhinitis (Hay Fever) | 0.5 | 1 | -1 |
Allergies | 1 | 0.6 | 0.67 |
Allergy to milk products | 0.6 | 0.3 | 1 |
Alopecia (Hair Loss) | 0 | 0 | |
Alzheimer's disease | 0.6 | 0.8 | -0.33 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.5 | 0.8 |
Ankylosing spondylitis | 0.7 | 0.1 | 6 |
Anorexia Nervosa | 0.4 | -0.4 | |
Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
Asthma | 0.5 | 0.5 | 0 |
Atherosclerosis | 0.2 | 0.6 | -2 |
Atrial fibrillation | 0.5 | 0.4 | 0.25 |
Autism | 1.8 | 2.1 | -0.17 |
Barrett esophagus cancer | 0.1 | 0 | 0 |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 0.2 | 0.1 | 1 |
Brain Trauma | 0.2 | 0.1 | 1 |
Carcinoma | 0.6 | 0.4 | 0.5 |
Celiac Disease | 0.6 | 1.4 | -1.33 |
Cerebral Palsy | 0.7 | 0.1 | 6 |
Chronic Fatigue Syndrome | 1.2 | 0.7 | 0.71 |
Chronic Kidney Disease | 0.2 | 0 | 0 |
Chronic Lyme | 0.1 | -0.1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0 | 0 |
Chronic Urticaria (Hives) | 0.7 | 0.3 | 1.33 |
Coagulation / Micro clot triggering bacteria | 0.4 | 0 | 0 |
Colorectal Cancer | 0.8 | 0.2 | 3 |
Constipation | 0.2 | 0.2 | |
Coronary artery disease | 0 | 0.1 | 0 |
COVID-19 | 3.6 | 2.5 | 0.44 |
Crohn's Disease | 1.7 | 0.7 | 1.43 |
cystic fibrosis | 0.4 | 0.3 | 0.33 |
deep vein thrombosis | 0.4 | 0 | 0 |
Depression | 2.6 | 1.9 | 0.37 |
Dermatomyositis | 0 | 0.2 | 0 |
Eczema | 0.2 | 0.5 | -1.5 |
Endometriosis | 0.7 | 0.2 | 2.5 |
Eosinophilic Esophagitis | 0.1 | -0.1 | |
Epilepsy | 0.6 | 0.7 | -0.17 |
Fibromyalgia | 0.8 | 1 | -0.25 |
Functional constipation / chronic idiopathic constipation | 1.7 | 0.7 | 1.43 |
gallstone disease (gsd) | 0.5 | 0.2 | 1.5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0 | 0 |
Generalized anxiety disorder | 0.4 | 1.3 | -2.25 |
giant cell arteritis | 0.3 | -0.3 | |
Glioblastoma | 0 | 0 | |
Graves' disease | 0.3 | 0 | 0 |
Halitosis | 0.2 | 0 | 0 |
Hashimoto's thyroiditis | 0.4 | 0.3 | 0.33 |
Hidradenitis Suppurativa | 0 | 0.1 | 0 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.2 | 0 | 0 |
hypercholesterolemia (High Cholesterol) | 0.4 | 0.2 | 1 |
hyperglycemia | 0.1 | 0.7 | -6 |
Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
hypertension (High Blood Pressure | 0.6 | 1.2 | -1 |
Hypothyroidism | 0.2 | -0.2 | |
Hypoxia | 0.2 | 0.2 | |
IgA nephropathy (IgAN) | 1.3 | -1.3 | |
Inflammatory Bowel Disease | 1.3 | 1.7 | -0.31 |
Insomnia | 0.1 | 0.1 | 0 |
Intelligence | 0.6 | 0.6 | |
Intracranial aneurysms | 0.1 | 0.1 | |
Irritable Bowel Syndrome | 1.7 | 1 | 0.7 |
Liver Cirrhosis | 1 | 0.8 | 0.25 |
Long COVID | 1.8 | 1.7 | 0.06 |
Low bone mineral density | 0 | 0 | |
Lung Cancer | 0.2 | 0.2 | 0 |
ME/CFS with IBS | 0.3 | 0.3 | 0 |
ME/CFS without IBS | 0.4 | 0.3 | 0.33 |
Menopause | 0.8 | 0.8 | |
Metabolic Syndrome | 1.3 | 2.6 | -1 |
Mood Disorders | 3.6 | 1.9 | 0.89 |
multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
Multiple Sclerosis | 1.3 | 1 | 0.3 |
Multiple system atrophy (MSA) | 0.4 | 0.2 | 1 |
Neuropathy (all types) | 0.1 | 0.1 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 1.5 | -2.75 |
NonCeliac Gluten Sensitivity | 0.2 | -0.2 | |
Obesity | 1.1 | 0.8 | 0.38 |
obsessive-compulsive disorder | 1 | 0.7 | 0.43 |
Osteoarthritis | 1 | 1 | |
Osteoporosis | 0.6 | 0.4 | 0.5 |
pancreatic cancer | 0.1 | 0.1 | |
Parkinson's Disease | 0.8 | 0.3 | 1.67 |
Polycystic ovary syndrome | 0.5 | 0.7 | -0.4 |
Postural orthostatic tachycardia syndrome | 0.3 | 0.2 | 0.5 |
Premenstrual dysphoric disorder | 0.2 | 0.2 | |
primary biliary cholangitis | 0 | 0.4 | 0 |
Psoriasis | 1 | 0.4 | 1.5 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.8 | -0.33 |
Rosacea | 0.2 | 0.3 | -0.5 |
Schizophrenia | 2.8 | 0.5 | 4.6 |
scoliosis | 0 | 0 | |
Sjögren syndrome | 0.5 | 0.9 | -0.8 |
Sleep Apnea | 0.2 | 0.1 | 1 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.7 | -1.33 |
Stress / posttraumatic stress disorder | 0.9 | 0.6 | 0.5 |
Systemic Lupus Erythematosus | 0.5 | 0.3 | 0.67 |
Tic Disorder | 0.1 | 0.2 | -1 |
Tourette syndrome | 0.1 | 0.1 | 0 |
Type 1 Diabetes | 0.4 | 0.4 | 0 |
Type 2 Diabetes | 1 | 2.3 | -1.3 |
Ulcerative colitis | 1 | 1.4 | -0.4 |
Unhealthy Ageing | 0.3 | 0.5 | -0.67 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.